{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:14:30Z","timestamp":1775499270854,"version":"3.50.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Modern Academy for Technology, Computer Science & Management"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The present study aimed to investigate the effects of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on insulin resistance and weight reduction through advanced glycation end-product modulation in patients newly diagnosed with type 2 diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was designed as a 12-week, randomized, controlled, parallel trial. A total of 120 patients with type 2 diabetes were selected and divided into two distinct groups: group I, patients who received gliclazide in combination with metformin, and group II, patients who received vildagliptin in combination with metformin. The percentage change in body weight was estimated along with serum advanced glycated end-product levels, glycated hemoglobin (HbA1c), and insulin resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Upon completing the study period, when vildagliptin was added to metformin instead of gliclazide, the results demonstrated a significant improvement in insulin resistance, a downregulation of serum levels of advanced glycation end products, glycated hemoglobin, and a decrease in body weight.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Vildagliptin showed a promising effect on improving type 2 diabetes mellitus\u2013related complications by reducing advanced glycated end-product levels and insulin resistance. Additionally, vildagliptin reveals a favorable impact on weight reduction and glycated hemoglobin values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00228-025-03894-8","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T04:58:34Z","timestamp":1754369914000},"page":"1593-1608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial"],"prefix":"10.1007","volume":"81","author":[{"given":"Toka","family":"Elemary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed E. A.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Zaafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"3894_CR1","doi-asserted-by":"publisher","unstructured":"Id SU, Rathnayake S (2023) Perspectives of older people with uncontrolled type 2 diabetes mellitus towards medication adherence : a qualitative study. d, 1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0289834","DOI":"10.1371\/journal.pone.0289834"},{"key":"3894_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"3894_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jphs.2021.07.004","volume":"147","author":"M Zhang","year":"2021","unstructured":"Zhang M, Yan W, Yu Y et al (2021) Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux. J Pharmacol Sci 147(3):234\u2013244. https:\/\/doi.org\/10.1016\/j.jphs.2021.07.004","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"3894_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15819-0","volume":"23","author":"HFM Farag","year":"2023","unstructured":"Farag HFM, Elrewany E, Abdel-Aziz BF, Sultan EA (2023) Prevalence and predictors of undiagnosed type 2 diabetes and prediabetes among adult Egyptians: a community-based survey. BMC Public Health 23(1):949. https:\/\/doi.org\/10.1186\/s12889-023-15819-0","journal-title":"BMC Public Health"},{"key":"3894_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.diabres.2018.07.025","volume":"144","author":"SH Assaad Khalil","year":"2018","unstructured":"Assaad Khalil SH, Megallaa MH, Rohoma KH et al (2018) Prevalence of type 2 diabetes mellitus in a sample of the adult population of Alexandria. Egypt. Diabetes Res Clin Pract 144:63\u201373. https:\/\/doi.org\/10.1016\/j.diabres.2018.07.025","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"3894_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2478\/enr-2022-0011","volume":"56","author":"HS Kassab","year":"2022","unstructured":"Kassab HS, Ismaeal MT, Elfattah TA, Elaaty A (2022) Diabetic foot care knowledge and practice in type 2 diabetes and relation to microvascular complications in Alexandria (Egypt). Endocr Regul 56(2):95\u2013103. https:\/\/doi.org\/10.2478\/enr-2022-0011","journal-title":"Endocr Regul"},{"issue":"31","key":"3894_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020707","volume":"99","author":"S Liu","year":"2020","unstructured":"Liu S, Wang X, Deng H et al (2020) Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: a protocol for systematic review and meta analysis. Medicine 99(31):E20707. https:\/\/doi.org\/10.1097\/MD.0000000000020707","journal-title":"Medicine"},{"issue":"9833","key":"3894_CR8","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/S0140-6736(12)60360-2","volume":"379","author":"RJ McCrimmon","year":"2012","unstructured":"McCrimmon RJ, Ryan CM, Frier BM (2012) Diabetes and cognitive dysfunction. Lancet 379(9833):2291\u20132299. https:\/\/doi.org\/10.1016\/S0140-6736(12)60360-2","journal-title":"Lancet"},{"issue":"4","key":"3894_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000337428","volume":"38","author":"KC Wang","year":"2012","unstructured":"Wang KC, Woung LC, Tsai MT et al (2012) Risk of Alzheimer\u2019s disease in relation to diabetes: a population-based cohort study. Neuroepidemiology 38(4):237\u2013244. https:\/\/doi.org\/10.1159\/000337428","journal-title":"Neuroepidemiology"},{"issue":"1","key":"3894_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.19045\/bspab.2023.120026","volume":"12","author":"N Hassan","year":"2023","unstructured":"Hassan N (2023) A review of the formation and role of advanced glycated end products and their receptor in the progression of diabetic complications. Pure Appl Biol 12(1):241\u2013251. https:\/\/doi.org\/10.19045\/bspab.2023.120026","journal-title":"Pure Appl Biol"},{"issue":"400","key":"3894_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-10458-7","volume":"52","author":"T Elemary","year":"2025","unstructured":"Elemary T, Nicola M, Abdelrahim ME, Zaafar D (2025) The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions. Mol Biol Rep 52:400.\u00a0https:\/\/doi.org\/10.1007\/s11033-025-10458-7","journal-title":"Mol Biol Rep 5"},{"issue":"3","key":"3894_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2337\/dc17-1740","volume":"41","author":"J Koska","year":"2018","unstructured":"Koska J, Saremi A, Howell S et al (2018) Advanced glycation end products, oxidation products, and incident cardiovascular events in patients with type 2 diabetes. Diabetes Care 41(3):570\u2013576. https:\/\/doi.org\/10.2337\/dc17-1740","journal-title":"Diabetes Care"},{"key":"3894_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310982","author":"K Gutowska","year":"2023","unstructured":"Gutowska K, Czajkowski K, Kury\u0142owicz A (2023) Receptor for the advanced glycation end products (RAGE) pathway in adipose tissue metabolism. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241310982","journal-title":"Int J Mol Sci"},{"issue":"14","key":"3894_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18147236","volume":"18","author":"J Salazar","year":"2021","unstructured":"Salazar J, Navarro C, Ortega \u00c1 et al (2021) Advanced glycation end products: new clinical and molecular perspectives. Int J Environ Res Public Health 18(14):7236. https:\/\/doi.org\/10.3390\/ijerph18147236","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"3894_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s00125-022-05821-3","volume":"66","author":"B Arshi","year":"2023","unstructured":"Arshi B, Chen J, Ikram MA et al (2023) Advanced glycation end-products, cardiac function and heart failure in the general population: the Rotterdam study. Diabetologia 66(3):472\u2013481. https:\/\/doi.org\/10.1007\/s00125-022-05821-3","journal-title":"Diabetologia"},{"key":"3894_CR16","doi-asserted-by":"publisher","unstructured":"Ega\u00f1a-Gorro\u00f1o L, L\u00f3pez-D\u00edez R, Yepuri G et al (2020) Receptor for advanced glycation end products (Rage) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. Front Cardiovasc Med 1\u201315. https:\/\/doi.org\/10.3389\/fcvm.2020.00037","DOI":"10.3389\/fcvm.2020.00037"},{"issue":"4","key":"3894_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","volume":"4","author":"Z Hegab","year":"2012","unstructured":"Hegab Z (2012) Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4(4):90. https:\/\/doi.org\/10.4330\/wjc.v4.i4.90","journal-title":"World J Cardiol"},{"issue":"15","key":"3894_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu14153086","volume":"14","author":"J Lee","year":"2022","unstructured":"Lee J, Yun JS, Ko SH (2022) Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. Nutrients 14(15):1\u201313. https:\/\/doi.org\/10.3390\/nu14153086","journal-title":"Nutrients"},{"issue":"7","key":"3894_CR19","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00394-019-02140-z","volume":"59","author":"MA Farhangi","year":"2020","unstructured":"Farhangi MA, Dehghan P, Namazi N (2020) Prebiotic supplementation modulates advanced glycation end-products (AGEs), soluble receptor for AGEs (sRAGE), and cardiometabolic risk factors through improving metabolic endotoxemia: a randomized-controlled clinical trial. Eur J Nutr 59(7):3009\u20133021. https:\/\/doi.org\/10.1007\/s00394-019-02140-z","journal-title":"Eur J Nutr"},{"issue":"1","key":"3894_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-022-00873-2","volume":"14","author":"T Jiang","year":"2022","unstructured":"Jiang T, Zhang Y, Dai F, Liu C, Hu H, Zhang Q (2022) Advanced glycation end products and diabetes and other metabolic indicators. Diabetol Metab Syndr 14(1):1\u201315. https:\/\/doi.org\/10.1186\/s13098-022-00873-2","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"3894_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2337\/db14-0215","volume":"64","author":"S Genuth","year":"2015","unstructured":"Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, Monnier VM (2015) Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 64(1):266\u2013278. https:\/\/doi.org\/10.2337\/db14-0215","journal-title":"Diabetes"},{"key":"3894_CR22","first-page":"3838","volume":"20","author":"R Singh","year":"2020","unstructured":"Singh R, Rao HK, Singh TG (2020) Advanced glycated end products (AGES) in diabetes and its complications: an insight. Plant Arch 20:3838\u20133841","journal-title":"Plant Arch"},{"issue":"1","key":"3894_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01397-2","volume":"19","author":"EO Melin","year":"2020","unstructured":"Melin EO, Dereke J, Hillman M (2020) Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study. Lipids Health Dis 19(1):1\u201310. https:\/\/doi.org\/10.1186\/s12944-020-01397-2","journal-title":"Lipids Health Dis"},{"issue":"8","key":"3894_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4239\/wjd.v14.i8.1146","volume":"14","author":"S Bansal","year":"2023","unstructured":"Bansal S, Burman A, Tripathi AK (2023) Advanced glycation end products: key mediator and therapeutic target of cardiovascular complications in diabetes. World J Diabetes 14(8):1146\u20131162. https:\/\/doi.org\/10.4239\/wjd.v14.i8.1146","journal-title":"World J Diabetes"},{"issue":"1","key":"3894_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-018-0060-3","volume":"24","author":"SL Fishman","year":"2018","unstructured":"Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L (2018) The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med 24(1):1\u201312. https:\/\/doi.org\/10.1186\/s10020-018-0060-3","journal-title":"Mol Med"},{"issue":"11","key":"3894_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9111100","volume":"9","author":"Y Takayanagi","year":"2020","unstructured":"Takayanagi Y, Yamanaka M, Fujihara J, Matsuoka Y, Gohto Y, Obana A, Tanito M (2020) Evaluation of relevance between advanced glycation end products and diabetic retinopathy stages using skin autofluorescence. Antioxidants 9(11):1\u201312. https:\/\/doi.org\/10.3390\/antiox9111100","journal-title":"Antioxidants"},{"issue":"3","key":"3894_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/jc.2014-2754","volume":"100","author":"PJJ Spauwen","year":"2015","unstructured":"Spauwen PJJ, Van Eupen MGA, K\u00f6hler S et al (2015) Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the Maastricht study. J Clin Endocrinol Metab 100(3):951\u2013960. https:\/\/doi.org\/10.1210\/jc.2014-2754","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3894_CR28","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/advances\/nmab072","volume":"12","author":"E Sharifi-Zahabi","year":"2021","unstructured":"Sharifi-Zahabi E, Sharafabad FH, Abdollahzad H et al (2021) Circulating advanced glycation end products and their soluble receptors in relation to all-cause and cardiovascular mortality: a systematic review and meta-analysis of prospective observational studies. Adv Nutr 12(6):2157\u20132171. https:\/\/doi.org\/10.1093\/advances\/nmab072","journal-title":"Adv Nutr"},{"issue":"1","key":"3894_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3233\/JAD-190639","volume":"72","author":"PS Chou","year":"2019","unstructured":"Chou PS, Wu MN, Yang CC et al (2019) Effect of advanced glycation end products on the progression of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 72(1):191\u2013197. https:\/\/doi.org\/10.3233\/JAD-190639","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"12","key":"3894_CR30","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.2337\/dc11-0958","volume":"34","author":"G Chen","year":"2011","unstructured":"Chen G, Cai L, Chen B et al (2011) Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 34(12):2586\u20132590. https:\/\/doi.org\/10.2337\/dc11-0958","journal-title":"Diabetes Care"},{"issue":"1","key":"3894_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-92630-0","volume":"11","author":"D Indyk","year":"2021","unstructured":"Indyk D, Bronowicka-Szyde\u0142ko A, Gamian A et al (2021) Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Sci Rep 11(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-021-92630-0","journal-title":"Sci Rep"},{"key":"3894_CR32","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.2147\/DMSO.S275898","volume":"13","author":"YT Wondmkun","year":"2020","unstructured":"Wondmkun YT (2020) Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes 13:3611\u20133616. https:\/\/doi.org\/10.2147\/DMSO.S275898","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3894_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2020\/5076858","volume":"2020","author":"H Alzamil","year":"2020","unstructured":"Alzamil H (2020) Elevated serum TNF- \u03b1 is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obes 2020:5\u20139. https:\/\/doi.org\/10.1155\/2020\/5076858","journal-title":"J Obes"},{"key":"3894_CR34","doi-asserted-by":"publisher","unstructured":"Zatterale F, Longo M, Naderi J et al (2020) Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol 1\u201320. https:\/\/doi.org\/10.3389\/fphys.2019.01607","DOI":"10.3389\/fphys.2019.01607"},{"issue":"4","key":"3894_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J et al (2016) Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23(4):591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005","journal-title":"Cell Metab"},{"issue":"16","key":"3894_CR36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.119.044865","volume":"141","author":"A Pandey","year":"2020","unstructured":"Pandey A, Patel KV, Bahnson JL et al (2020) Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD trial. Circulation 141(16):1295\u20131306. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044865","journal-title":"Circulation"},{"issue":"1","key":"3894_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12944-023-01985-y","volume":"22","author":"J Meng","year":"2023","unstructured":"Meng J, Yan R, Zhang C et al (2023) Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus. Lipids Health Dis 22(1):219. https:\/\/doi.org\/10.1186\/s12944-023-01985-y","journal-title":"Lipids Health Dis"},{"key":"3894_CR38","doi-asserted-by":"publisher","unstructured":"Jash K, Gondaliya P, Kirave P et al (2019) Cognitive dysfunction : a growing link between diabetes and Alzheimer\u2019 s disease 144\u2013164. https:\/\/doi.org\/10.1002\/ddr.21579","DOI":"10.1002\/ddr.21579"},{"key":"3894_CR39","doi-asserted-by":"publisher","unstructured":"Werida R, Kabel M, Omran G et al (2020) Comparative clinical study evaluating the effect of adding vildagliptin versus glimepiride to ongoing metformin therapy on diabetic patients with symptomatic coronary artery disease. Diabetes Res Clin Prac 108473. https:\/\/doi.org\/10.1016\/j.diabres.2020.108473","DOI":"10.1016\/j.diabres.2020.108473"},{"key":"3894_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154295","volume":"109","author":"AP Stoian","year":"2020","unstructured":"Stoian AP, Sachinidis A, Stoica RA et al (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109:154295. https:\/\/doi.org\/10.1016\/j.metabol.2020.154295","journal-title":"Metabolism"},{"issue":"3","key":"3894_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1074248418817345","volume":"24","author":"AR El-Naggar","year":"2019","unstructured":"El-Naggar AR, Zaafar D, Elyamany M et al (2019) The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients. J Cardiovasc Pharmacol Ther 24(3):254\u2013261. https:\/\/doi.org\/10.1177\/1074248418817345","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"3894_CR42","doi-asserted-by":"publisher","unstructured":"Ding Y, Liu Y, Qu Y et al (2022) Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for type 2 diabetes mellitus therapy: a meta-analysis. Euro Rev Med Pharmacol Sci 26(8):2802\u20132817. https:\/\/doi.org\/10.26355\/eurrev_202204_28611","DOI":"10.26355\/eurrev_202204_28611"},{"issue":"9","key":"3894_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.44548","volume":"15","author":"S Erande","year":"2023","unstructured":"Erande S, Mukhopadhyay J, Dange A et al (2023) Efficacy and safety of a fixed-dose combination of vildagliptin and pioglitazone in Indian patients with type 2 diabetes mellitus: a randomized, open-label, comparative, phase III study. Cureus 15(9):1\u201311. https:\/\/doi.org\/10.7759\/cureus.44548","journal-title":"Cureus"},{"issue":"3","key":"3894_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/acprof:oso\/9780199241323.003.0025","volume":"81","author":"H Kong","year":"2014","unstructured":"Kong H, West S, States U (2014) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 81(3):14\u201318. https:\/\/doi.org\/10.1093\/acprof:oso\/9780199241323.003.0025","journal-title":"J Am Coll Dent"},{"key":"3894_CR45","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA Elsayed","year":"2023","unstructured":"Elsayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes\u20142023. Diabetes Care 46:S19\u2013S40. https:\/\/doi.org\/10.2337\/dc23-S002","journal-title":"Diabetes Care"},{"key":"3894_CR46","doi-asserted-by":"publisher","unstructured":"Perry RC et al (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 24(3):465\u201371. https:\/\/doi.org\/10.2337\/diacare.24.3.465","DOI":"10.2337\/diacare.24.3.465"},{"issue":"1","key":"3894_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-018-0331-8","volume":"10","author":"LA Leiter","year":"2018","unstructured":"Leiter LA, Shestakova MV, Satman I (2018) Effectiveness of Gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial ISRCTN00943368 ISRCTN. Diabetol Metab Syndr 10(1):1\u20138. https:\/\/doi.org\/10.1186\/s13098-018-0331-8","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"3894_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","volume":"103","author":"AJ Garber","year":"1997","unstructured":"Garber AJ, Duncan TG, Goodman AM et al (1997) Efficacy of Metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103(6):491\u2013497. https:\/\/doi.org\/10.1016\/S0002-9343(97)00254-4","journal-title":"Am J Med"},{"issue":"6","key":"3894_CR49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s13300-022-01269-1","volume":"13","author":"Y Schnaars","year":"2022","unstructured":"Schnaars Y, Gaikwad S, Gottwald-Hostalek U et al (2022) Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and metformin versus respective originator products in healthy volunteers. Diabetes Ther 13(6):1215\u20131229. https:\/\/doi.org\/10.1007\/s13300-022-01269-1","journal-title":"Diabetes Ther"},{"key":"3894_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108042","volume":"162","author":"I El Ebrashy","year":"2020","unstructured":"El Ebrashy I, El Kafrawy N, Raouf R et al (2020) Effectiveness, safety, and tolerability of vildagliptin or vildagliptin\/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: the OMEGA study. Diabetes Res Clin Pract 162:108042. https:\/\/doi.org\/10.1016\/j.diabres.2020.108042","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"3894_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/japtr.JAPTR_18_20","volume":"11","author":"H Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy H, Sami O, Hussain N, Al-Gareeb A (2020) Metformin and\/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: the intriguing effect. J Adv Pharm Technol Res 11(3):142\u2013147. https:\/\/doi.org\/10.4103\/japtr.JAPTR_18_20","journal-title":"J Adv Pharm Technol Res"},{"issue":"12","key":"3894_CR52","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1111\/dom.15958","volume":"26","author":"ZA ElKabbany","year":"2024","unstructured":"ElKabbany ZA, Ismail EAR, Hamed ET, Elbarbary NS (2024) The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: a randomized controlled trial. Diabetes Obes Metab 26(12):5857\u20135869. https:\/\/doi.org\/10.1111\/dom.15958","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"3894_CR53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47190","volume":"15","author":"P Panneerselvam","year":"2023","unstructured":"Panneerselvam P, Biswas D, Singh H et al (2023) Real-world observational study on vildagliptin with insulin (VIL-INS) or vildagliptin and metformin with insulin (VIL-MET-INS) therapy in Indian patients with type 2 diabetes mellitus. Cureus 15(10):e47190. https:\/\/doi.org\/10.7759\/cureus.47190","journal-title":"Cureus"},{"issue":"6","key":"3894_CR54","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s13300-022-01269-1","volume":"13","author":"Y Schnaars","year":"2022","unstructured":"Schnaars Y, Gaikwad S, Gottwald-Hostalek U, Klingberg U, Vadla HKC, Prathap VR (2022) Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and metformin versus respective originator products in healthy volunteers. Diabetes Ther 13(6):1215\u20131229. https:\/\/doi.org\/10.1007\/s13300-022-01269-1","journal-title":"Diabetes Ther"},{"issue":"2","key":"3894_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/afpuc-2023-0019","volume":"70","author":"J Shiekmydeen","year":"2023","unstructured":"Shiekmydeen J, Siddiqi T, Chakraborty K, Khalaf S, Albarazi M, Eqtefan I, Sliva J (2023) A randomized, two-treatments, two-periods, crossover, open label, laboratory-blind, single dose bioequivalence study between vildagliptin\/metformin 50 mg\/1000 mg film coated tablets (Sensityn\u00ae) and Galvusmet\u00ae 50 mg\/1000 mg film coated tablets in healthy adults under fed conditions. Euro Pharma J Sciendo 70(2):1\u20139. https:\/\/doi.org\/10.2478\/afpuc-2023-0019","journal-title":"Euro Pharma J Sciendo"},{"issue":"12","key":"3894_CR56","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/1440-1681.13561","volume":"48","author":"SH Elhini","year":"2021","unstructured":"Elhini SH, Hussien AK, Omran AAE et al (2021) Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clin Exp Pharmacol Physiol 48(12):1589\u20131602. https:\/\/doi.org\/10.1111\/1440-1681.13561","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"3894_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0100562","volume":"9","author":"DK Zaafar","year":"2014","unstructured":"Zaafar DK, Zaitone SA, Moustafa YM (2014) Role of Metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation. PLoS One 9(6):1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0100562","journal-title":"PLoS One"},{"key":"3894_CR58","doi-asserted-by":"publisher","unstructured":"Jeppsson J, Kobold U, Barr J et al (2002) Approved IFCC reference method for the measurement of HbA 1c in human blood 36(1):78\u201389. https:\/\/doi.org\/10.1515\/CCLM.2002.016","DOI":"10.1515\/CCLM.2002.016"},{"issue":"7","key":"3894_CR59","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"3894_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1057\/978-1-349-96073-6_16356","volume":"46","author":"THE Journal","year":"2024","unstructured":"Journal THE, Clinical OF (2024) American Diabetes Association (ADA). Grants Register 46:64\u201364. https:\/\/doi.org\/10.1057\/978-1-349-96073-6_16356","journal-title":"Grants Register"},{"issue":"8","key":"3894_CR61","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/dmrr.2437","volume":"29","author":"K Sakata","year":"2013","unstructured":"Sakata K, Hayakawa M, Yano Y et al (2013) Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev 29(8):624\u2013630. https:\/\/doi.org\/10.1002\/dmrr.2437","journal-title":"Diabetes Metab Res Rev"},{"issue":"10208","key":"3894_CR62","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","volume":"394","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P et al (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394(10208):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(19)32131-2","journal-title":"Lancet"},{"key":"3894_CR63","doi-asserted-by":"publisher","unstructured":"Heli H Amin, Dr. Hirenkumar R Chaudhary (2024) Comparative analysis of effectiveness and safety between metformin monotherapy and the combined use of metformin with vildagliptin in individuals diagnosed with type 2 diabetes mellitus. J Adv Zool 45(1):420\u2013427. https:\/\/doi.org\/10.53555\/jaz.v45i1.3913","DOI":"10.53555\/jaz.v45i1.3913"},{"issue":"3","key":"3894_CR64","doi-asserted-by":"publisher","first-page":"413","DOI":"10.6026\/97320630017413","volume":"17","author":"S Das","year":"2021","unstructured":"Das S, Gupta AK, Bandyopadhyaya B, Darla BH, Arya V, Abhyankar M, Revankar S (2021) Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management. Bioinformation 17(3):413\u2013423. https:\/\/doi.org\/10.6026\/97320630017413","journal-title":"Bioinformation"},{"issue":"June","key":"3894_CR65","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.2147\/DMSO.S315227","volume":"14","author":"V Mohan","year":"2021","unstructured":"Mohan V, Zargar A, Chawla M et al (2021) Efficacy of a combination of Metformin and vildagliptin in comparison to Metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study. Diabetes, Metab Syndr Obes 14(June):2925\u20132933. https:\/\/doi.org\/10.2147\/DMSO.S315227","journal-title":"Diabetes, Metab Syndr Obes"},{"key":"3894_CR66","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/DMSO.S339331","volume":"15","author":"A Fouad Algendy","year":"2022","unstructured":"Fouad Algendy A, Illigens B, Alyazeedi A (2022) Increased frequency of severe hypoglycemia with the modified-release gliclazide compared to glimepiride in diabetic older adults; propensity score-adjusted analysis. Diabetes Metab Syndr Obes 1563\u20131575. https:\/\/doi.org\/10.2147\/DMSO.S339331","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"3894_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-020-0518-5","volume":"20","author":"M Bareti\u0107","year":"2020","unstructured":"Bareti\u0107 M, Brali\u0107 Lang V (2020) Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia. BMC Endocr Disord 20(1):1\u20138. https:\/\/doi.org\/10.1186\/s12902-020-0518-5","journal-title":"BMC Endocr Disord"},{"key":"3894_CR68","doi-asserted-by":"publisher","unstructured":"Hong AR, Lee J, Jeong E et al (2015) Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using Metformin and sulfonylurea ( VISUAL study ): a randomized trial. Diabetes Res Clin Prac 1\u20138. https:\/\/doi.org\/10.1016\/j.diabres.2015.04.019","DOI":"10.1016\/j.diabres.2015.04.019"},{"issue":"5","key":"3894_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.39204","volume":"15","author":"G Sridhar","year":"2023","unstructured":"Sridhar G, Pandit K, Warrier S et al (2023) Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review. Cureus 15(5):1\u20139. https:\/\/doi.org\/10.7759\/cureus.39204","journal-title":"Cureus"},{"issue":"1","key":"3894_CR70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/bjem.bjem_20_22","volume":"2","author":"M Rahaman","year":"2023","unstructured":"Rahaman M, Das A, Ray S et al (2023) Effects on glycemic control by combination therapy of gliclazide-metformin and insulin in type 2 diabetes mellitus patients. Bangladesh Journal of Endocrinology and Metabolism 2(1):51. https:\/\/doi.org\/10.4103\/bjem.bjem_20_22","journal-title":"Bangladesh Journal of Endocrinology and Metabolism"},{"issue":"6","key":"3894_CR71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjaed\/mkw075","volume":"17","author":"DJ Stubbs","year":"2017","unstructured":"Stubbs DJ, Levy N, Dhatariya K (2017) Diabetes medication pharmacology. BJA Educ 17(6):198\u2013207. https:\/\/doi.org\/10.1093\/bjaed\/mkw075","journal-title":"BJA Educ"},{"issue":"7","key":"3894_CR72","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1185\/03007995.2011.579951","volume":"27","author":"M Hassanein","year":"2011","unstructured":"Hassanein M, Hanif W, Malik W et al (2011) Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 27(7):1367\u20131374. https:\/\/doi.org\/10.1185\/03007995.2011.579951","journal-title":"Curr Med Res Opin"},{"key":"3894_CR73","doi-asserted-by":"publisher","unstructured":"Aya Gamal M, Gamal AA, Ibrahim OM et al (2021) Effect of vildagliptin versus vildagliptin plus metformin on nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. J Diabetes Metab 12:890. https:\/\/doi.org\/10.35248\/2155-6156.21.12.890","DOI":"10.35248\/2155-6156.21.12.890"},{"issue":"4","key":"3894_CR74","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1530\/EC-18-0523","volume":"8","author":"XJ Zhou","year":"2019","unstructured":"Zhou XJ, Ding L, Liu JX et al (2019) Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in chinese diabetes: a randomized clinical trial. Endocr Connect 8(4):318\u2013325. https:\/\/doi.org\/10.1530\/EC-18-0523","journal-title":"Endocr Connect"},{"key":"3894_CR75","doi-asserted-by":"publisher","unstructured":"Sharma V, Chawla S, Garg S et al (2024) Efficacy and safety of vildagliptin and remogliflozin as add-on therapy to metformin in patients of type 2 diabetes mellitus: an open-label comparative study. Sultan Qaboos University Med J 1(1). https:\/\/doi.org\/10.18295\/squmj.1.2024.006","DOI":"10.18295\/squmj.1.2024.006"},{"key":"3894_CR76","doi-asserted-by":"publisher","unstructured":"Uddin MF, Khan MA et al (2024) Real-world evidence on the effectiveness and safety of Gliclazide MR 60 mg in Bangladeshi patients with type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study. J Comparative Effect Res 13(2):e230132. https:\/\/doi.org\/10.57264\/cer-2023-0132","DOI":"10.57264\/cer-2023-0132"},{"key":"3894_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108880","volume":"177","author":"L Ying","year":"2021","unstructured":"Ying L, Shen Y, Zhang Y et al (2021) Association of advanced glycation end products with diabetic retinopathy in type 2 diabetes mellitus. Diabetes Res Clin Pract 177:108880. https:\/\/doi.org\/10.1016\/j.diabres.2021.108880","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"3894_CR78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5551\/jat.RV17014","volume":"25","author":"N Katakami","year":"2018","unstructured":"Katakami N (2018) Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J Atheroscler Thromb 25(1):27\u201339. https:\/\/doi.org\/10.5551\/jat.RV17014","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"3894_CR79","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/nutrit\/nuab020","volume":"80","author":"JS Oliveira","year":"2022","unstructured":"Oliveira JS, de Almeida C, de Souza \u00c2MN et al (2022) Effect of dietary advanced glycation end-products restriction on type 2 diabetes mellitus control: a systematic review. Nutr Rev 80(2):294\u2013305. https:\/\/doi.org\/10.1093\/nutrit\/nuab020","journal-title":"Nutr Rev"},{"issue":"13","key":"3894_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells12131684","volume":"12","author":"M Portero-Otin","year":"2023","unstructured":"Portero-Otin M, de la Maza MP, Uribarri J (2023) Dietary advanced glycation end products: their role in the insulin resistance of aging. Cells 12(13):1\u201313. https:\/\/doi.org\/10.3390\/cells12131684","journal-title":"Cells"},{"issue":"10","key":"3894_CR81","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00125-016-4053-x","volume":"59","author":"H Vlassara","year":"2016","unstructured":"Vlassara H, Cai W, Tripp E et al (2016) Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia 59(10):2181\u20132192. https:\/\/doi.org\/10.1007\/s00125-016-4053-x","journal-title":"Diabetologia"},{"key":"3894_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/nu12010238","author":"S De La Cruz-Ares","year":"2020","unstructured":"De La Cruz-Ares S, Cardelo MP, Guti\u00e9rrez-Mariscal FM et al (2020) Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: from the CORDIOPREV study. Nutrients. https:\/\/doi.org\/10.3390\/nu12010238","journal-title":"Nutrients"},{"issue":"4","key":"3894_CR83","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3233\/JAD-210131","volume":"82","author":"R Lotan","year":"2021","unstructured":"Lotan R, Ganmore I, Livny A et al (2021) Effect of advanced glycation end products on cognition in older adults with type 2 diabetes: results from a pilot clinical trial. J Alzheimers Dis 82(4):1785\u20131795. https:\/\/doi.org\/10.3233\/JAD-210131","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"3894_CR84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MCA.0b013e3282fec058","volume":"19","author":"G Basta","year":"2008","unstructured":"Basta G, Berti S, Cocci F et al (2008) Plasma N-\u03b5-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 19(5):299\u2013305. https:\/\/doi.org\/10.1097\/MCA.0b013e3282fec058","journal-title":"Coron Artery Dis"},{"key":"3894_CR85","doi-asserted-by":"publisher","unstructured":"Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S ichi (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate\/insulin-like growth factor II receptor. Cardiovasc Diabetol 12(1):1\u20139. https:\/\/doi.org\/10.1186\/1475-2840-12-125","DOI":"10.1186\/1475-2840-12-125"},{"key":"3894_CR86","doi-asserted-by":"publisher","unstructured":"Nagayama D, Kawana H, Watanabe Y et al (2024) Effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the parameters of glucose metabolism and the cardio-ankle vascular index in individuals with type 2 diabetes. J Clin Med 13(2). https:\/\/doi.org\/10.3390\/jcm13020481","DOI":"10.3390\/jcm13020481"},{"key":"3894_CR87","doi-asserted-by":"publisher","unstructured":"Puddu A, Sanguineti R, Maggi D, Nicol\u00f2 M, Traverso CE, Cordera R, Viviani GL (2019) Advanced glycation end-products and hyperglycemia increase angiopoietin-2 production by impairing angiopoietin-1-tie-2 system. J Diabetes Res 6198495. https:\/\/doi.org\/10.1155\/2019\/6198495.","DOI":"10.1155\/2019\/6198495"},{"issue":"4","key":"3894_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018782","volume":"6","author":"T Shu","year":"2011","unstructured":"Shu T, Zhu Y, Wang H, Lin Y, Ma Z, Han X (2011) AGEs decrease insulin synthesis in pancreatic \u03b2-cell by repressing Pdx-1 protein expression at the post-translational level. PLoS One 6(4):e18782. https:\/\/doi.org\/10.1371\/journal.pone.0018782","journal-title":"PLoS One"},{"key":"3894_CR89","doi-asserted-by":"publisher","unstructured":"Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F (2013) An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflammation 1\u20139. https:\/\/doi.org\/10.1155\/2013\/591056","DOI":"10.1155\/2013\/591056"},{"issue":"9","key":"3894_CR90","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/092986610791760423","volume":"17","author":"H Unoki-Kubota","year":"2010","unstructured":"Unoki-Kubota H, Yamagishi S, Takeuchi M, Bujo H, Saito Y (2010) Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett 17(9):1177\u20131181. https:\/\/doi.org\/10.2174\/092986610791760423","journal-title":"Protein Pept Lett"},{"key":"3894_CR91","doi-asserted-by":"publisher","unstructured":"Zhang Y, Huang X, Yuan Y (2019) Linagliptin protects human chondrogenic ATDC5 cells against advanced glycation end products (AGEs)-induced apoptosis via a mitochondria-dependent pathway. Chemico-Biol Interact 108901. https:\/\/doi.org\/10.1016\/j.cbi.2019.108901","DOI":"10.1016\/j.cbi.2019.108901"},{"key":"3894_CR92","doi-asserted-by":"publisher","unstructured":"Zaki MK, Abed MN, Alassaf FA (2024) Antidiabetic agents and bone quality: a focus on glycation end products and incretin pathway modulations. J Bone Metabol 31(3):169\u2013181. https:\/\/doi.org\/10.11005\/jbm.2024.31.3.169","DOI":"10.11005\/jbm.2024.31.3.169"},{"issue":"4","key":"3894_CR93","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ddr.21779","volume":"82","author":"R Kumar","year":"2021","unstructured":"Kumar R, Bhargava P, Suchal K, Bhatia J, Arya DS (2021) Targeting AGE-RAGE signaling pathway by saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats. Drug Dev Res 82(4):589\u2013597. https:\/\/doi.org\/10.1002\/ddr.21779","journal-title":"Drug Dev Res"},{"issue":"8","key":"3894_CR94","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/dmrr.2437","volume":"29","author":"K Sakata","year":"2013","unstructured":"Sakata K, Hayakawa M, Yano Y, Tamaki N, Yokota N, Eto T, Watanabe R, Hirayama N, Matsuo T, Kuroki K, Sagara S, Mishima O, Koga M, Nagata N, Nishino Y, Kitamura K, Kario K, Takeuchi M, Yamagishi S (2013) Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev 29(8):624\u2013630. https:\/\/doi.org\/10.1002\/dmrr.2437","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"3894_CR95","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.dsx.2020.07.036","volume":"14","author":"KA Adeshara","year":"2020","unstructured":"Adeshara KA, Bangar NS, Doshi PR et al (2020) Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study. Diabetes Metab Syndr 14(5):1449\u20131458. https:\/\/doi.org\/10.1016\/j.dsx.2020.07.036","journal-title":"Diabetes Metab Syndr"},{"issue":"10208","key":"3894_CR96","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","volume":"394","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, Chiang YT, Stumvoll M, Del Prato S (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394(10208):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(19)32131-2","journal-title":"Lancet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03894-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:21:53Z","timestamp":1759994513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03894-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3894"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03894-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}